EP4456885A1 — Epinephrine premix formulations and uses thereof
Assigned to Baxter Healthcare SA · Expires 2024-11-06 · 2y expired
What this patent protects
A pharmaceutical premix formulation comprising from about 10 mcg/ml to about 70 mcg/ml epinephrine and a salt is described, wherein the formulation is an aqueous, premix formulation and has a pH from about 2 to about 6. Uses and systems including the epinephrine premix formulatio…
USPTO Abstract
A pharmaceutical premix formulation comprising from about 10 mcg/ml to about 70 mcg/ml epinephrine and a salt is described, wherein the formulation is an aqueous, premix formulation and has a pH from about 2 to about 6. Uses and systems including the epinephrine premix formulation are also provided.
Drugs covered by this patent
- Unithroid (LEVOTHYROXINE SODIUM) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.